A new FLT3 inhibitor with two cases: the gilteritinib experience.

Istemi Serin, Mehmet Hilmi Dogu, Gulben Erdem Huq, Osman Yokus

Open access · greenAbstract readCase Reports

In one paragraph

Article in American journal of blood research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 90% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 3 countries.

Istemi SerinDepartment of Hematology Istanbul, Istanbul Training and Research Hospital, University of Health Science Istanbul, Turkey.

Mehmet Hilmi DoguDepartment of Internal Medicine and Hematology, Liv Hospital Ulus, Istinye University Istanbul, Turkey.

Gulben Erdem HuqDepartment of Pathology Istanbul, Istanbul Training and Research Hospital, University of Health Science Istanbul, Turkey.

Osman YokusDepartment of Hematology Istanbul, Istanbul Training and Research Hospital, University of Health Science Istanbul, Turkey.

University of Health Science · KHLiv Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn acute myeloid leukemia (AML), a heterogeneous group of leukemias, there are various factors to determine prognosis. Among these prognostic factors, cytogenetic results are increasing in importance day by day. FLT3 mutations are among the most common molecular abnormalities in AML, patients with recurrent or refractory (R/R) AML with this mutation have a low response rate to salvage therapy. Gilteritinib has activity against FLT3, ALK and AXL. This article shall present two cases, for which Gilteritinib was used, a new FLT3 inhibitor, and the results of the treatment. Case 1: A 52-year-old female patient presented to the emergency clinic with weakness and fever. In initial biochemical analysis, leukocyte was 104000/mm DISCUSSION AND

conclusionUnlike other FLT 3 inhibitors, Gilteritinib has been shown to be a highly effective agent in R/R AML with FLT3 mutations. Being the first data to be reported from Turkey, we think it would be quite guiding the titular.

Indexed as

Acute myeloid leukemiaFLT3gilteritinibprognosisrefractory

Identifiers

PMID34322291

PMCPMC8303015

OpenAlexW3186395507

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.